Literature DB >> 501147

Excretion pathways of amphotericin B.

P C Craven, T M Ludden, D J Drutz, W Rogers, K A Haegele, H B Skrdlant.   

Abstract

The role of the biliary system in excretion of amphotericin B was explored in a dog model that allowed either external diversion of all bile or complete biliary obstruction. In dogs with biliary diversion, which were given a single dose of amphotericin B intravenously, excretion of amphotericin B in the bile lasted for seven to 10 days and accounted for only 3% +/- 2% (mean +/- SD) of the dose, whereas excretion in the urine was prolonged (23--35 days) and greater (21% +/- 5% of the dose); the stool contained no amphotericin B. However, bile salt depletion may have depressed biliary excretion of amphotericin B: in a dog with an intact biliary system, 19% of the dose was excreted in the stool over 11 days. In dogs given amphotericin B daily, serum levels were 19% +/- 3% higher during periods of biliary obstruction than during periods of free bile flow (P less than 0.05). Thus, excretion of amphotericin B in the bile (less than or equal to 19% of the dose) and in the urine (21% of the dose) accounted for a minority of total drug clearance. Nevertheless, prolonged excretion of amphotericin B by these routes after a single dose suggests that infrequent doses of amphotericin B may provide effective treatment for certain forms of fungal infection.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 501147     DOI: 10.1093/infdis/140.3.329

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Choledochal fungal ball. An unusual cause of biliary obstruction.

Authors:  F Ho; W J Snape; R Venegas; J Lechago; S Klein
Journal:  Dig Dis Sci       Date:  1988-08       Impact factor: 3.199

2.  High-pressure liquid chromatographic method for determination of Sch 28191 in biological fluids.

Authors:  H Kim; C Lin
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

3.  Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys.

Authors:  H Kim; D Loebenberg; A Marco; S Symchowicz; C Lin
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

4.  Quantitative extraction of amphotericin B from serum and its determination by high-pressure liquid chromatography.

Authors:  P R Bach
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

6.  Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans.

Authors:  F Bistoni; A Vecchiarelli; R Mazzolla; P Puccetti; P Marconi; E Garaci
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Risk factors of ventricular fibrillation during rapid amphotericin B infusion.

Authors:  P C Craven; D H Gremillion
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling.

Authors:  G Robbie; W L Chiou
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

Review 9.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

Review 10.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.